NanoString Technologies Inc. (NASDAQ:NSTG) Director Charles P. Waite, Jr. sold 588,024 shares of the business’s stock in a transaction on Monday, November 21st. The shares were sold at an average price of $21.25, for a total transaction of $12,495,510.00. Following the completion of the transaction, the director now directly owns 1,707 shares of the company’s stock, valued at approximately $36,273.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NanoString Technologies Inc. (NASDAQ:NSTG) opened at 23.05 on Friday. The company’s market capitalization is $484.14 million. NanoString Technologies Inc. has a 52-week low of $11.30 and a 52-week high of $23.45. The company has a 50-day moving average of $21.05 and a 200 day moving average of $16.65.

NanoString Technologies (NASDAQ:NSTG) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.01. The business earned $23.90 million during the quarter, compared to the consensus estimate of $23.46 million. NanoString Technologies had a negative net margin of 53.02% and a negative return on equity of 784.63%. The firm’s revenue was up 52.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.49) EPS. Analysts predict that NanoString Technologies Inc. will post ($2.21) earnings per share for the current year.

Insider Buying and Selling by Quarter for NanoString Technologies (NASDAQ:NSTG)

Several equities analysts have recently issued reports on NSTG shares. Zacks Investment Research raised shares of NanoString Technologies from a “sell” rating to a “hold” rating in a report on Tuesday. BTIG Research reissued a “buy” rating and issued a $20.00 price target on shares of NanoString Technologies in a report on Friday, August 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.50.

Institutional investors have recently added to or reduced their stakes in the stock. Apriem Advisors acquired a new position in NanoString Technologies during the third quarter valued at about $120,000. American International Group Inc. increased its position in NanoString Technologies by 14.2% in the second quarter. American International Group Inc. now owns 8,528 shares of the company’s stock valued at $107,000 after buying an additional 1,062 shares during the last quarter. BlackRock Advisors LLC increased its position in NanoString Technologies by 25.4% in the third quarter. BlackRock Advisors LLC now owns 8,745 shares of the company’s stock valued at $175,000 after buying an additional 1,771 shares during the last quarter. Nationwide Fund Advisors increased its position in NanoString Technologies by 7.2% in the second quarter. Nationwide Fund Advisors now owns 9,064 shares of the company’s stock valued at $114,000 after buying an additional 612 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new position in NanoString Technologies during the second quarter valued at about $130,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Charles P. Waite, Jr. Sells 588,024 Shares of NanoString Technologies Inc. (NSTG) Stock” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/25/charles-p-waite-jr-sells-588024-shares-of-nanostring-technologies-inc-nstg-stock.html.

NanoString Technologies Company Profile

NanoString Technologies, Inc develops and manufactures intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

5 Day Chart for NASDAQ:NSTG

Receive News & Stock Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related stocks with our FREE daily email newsletter.